E

Evrofarma SA
ATHEX:EVROF

Watchlist Manager
Evrofarma SA
ATHEX:EVROF
Watchlist
Price: 3.77 EUR
Market Cap: €51.5m

Balance Sheet

Balance Sheet Decomposition
Evrofarma SA

Balance Sheet
Evrofarma SA

Rotate your device to view
Balance Sheet
Currency: EUR
Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
4
0
0
0
0
1
1
0
1
0
0
0
0
0
0
1
1
0
3
0
1
1
3
Cash
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash Equivalents
4
0
0
0
0
1
1
0
1
0
0
0
0
0
0
1
1
0
3
0
1
1
3
Short-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Receivables
9
9
11
9
9
12
15
13
12
10
8
10
10
10
11
12
12
10
12
14
12
9
7
Accounts Receivables
5
6
5
8
6
10
13
11
11
9
6
8
10
10
11
12
12
10
12
14
12
9
7
Other Receivables
4
4
5
1
3
1
2
2
1
1
2
2
0
0
0
0
0
0
0
0
0
0
0
Inventory
7
5
5
3
4
5
4
5
5
3
2
2
4
3
3
3
3
3
3
3
5
6
7
Other Current Assets
2
3
2
2
2
2
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
Total Current Assets
21
18
18
14
15
20
20
18
18
13
12
12
14
14
15
17
16
13
19
17
19
16
18
PP&E Net
17
18
25
26
26
27
31
34
37
35
35
32
31
29
28
27
27
27
27
29
29
30
30
PP&E Gross
17
18
25
26
26
27
31
34
37
35
35
0
0
0
0
0
0
0
0
0
0
0
0
Accumulated Depreciation
7
8
9
11
13
15
16
17
19
20
23
0
0
0
0
0
0
0
0
0
0
0
0
Intangible Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Note Receivable
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Long-Term Investments
3
3
3
2
3
3
2
2
2
3
1
1
1
1
1
1
1
1
1
1
1
1
1
Other Long-Term Assets
4
4
1
0
1
1
0
1
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
Total Assets
45
N/A
42
-6%
47
+13%
42
-10%
45
+6%
51
+13%
53
+5%
55
+4%
58
+4%
53
-8%
49
-8%
47
-4%
47
+1%
44
-6%
44
-1%
45
+3%
44
-2%
41
-7%
46
+13%
47
+0%
49
+5%
47
-3%
48
+2%
Liabilities
Accounts Payable
1
2
1
4
5
7
4
8
5
4
5
7
8
6
6
8
8
5
7
7
7
6
6
Accrued Liabilities
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Short-Term Debt
2
1
2
0
0
0
3
0
5
4
24
0
0
0
0
7
6
8
1
1
2
4
10
Current Portion of Long-Term Debt
4
4
3
8
10
7
10
14
12
15
0
9
7
7
9
11
2
9
3
3
3
3
2
Other Current Liabilities
1
1
2
0
1
1
1
0
2
1
1
0
0
0
0
0
0
0
0
0
0
0
0
Total Current Liabilities
8
8
8
13
15
15
17
22
23
24
31
16
15
13
15
26
16
22
11
10
13
13
18
Long-Term Debt
19
18
16
10
9
15
15
12
13
10
1
14
16
15
11
1
10
1
17
18
16
13
5
Deferred Income Tax
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
Minority Interest
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Liabilities
0
0
0
3
5
5
5
5
6
6
7
6
7
6
6
6
6
5
5
4
5
5
6
Total Liabilities
29
N/A
26
-9%
23
-11%
26
+10%
29
+13%
35
+19%
37
+8%
40
+6%
42
+6%
40
-5%
39
-3%
37
-4%
38
+3%
35
-9%
34
-3%
34
+2%
33
-5%
29
-10%
33
+14%
34
+1%
35
+3%
31
-11%
30
-2%
Equity
Common Stock
8
8
10
10
10
10
10
10
12
12
12
12
12
12
12
12
12
12
12
12
12
6
6
Retained Earnings
5
4
5
6
5
5
5
5
3
0
3
3
4
3
3
2
1
1
0
0
1
10
12
Additional Paid In Capital
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
Other Equity
2
2
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Equity
16
N/A
16
-1%
24
+52%
17
-30%
16
-6%
16
+2%
16
0%
16
-2%
16
+0%
13
-19%
10
-21%
10
-4%
9
-4%
10
+6%
10
+4%
11
+5%
12
+9%
12
+2%
13
+9%
13
-3%
14
+11%
16
+16%
18
+10%
Total Liabilities & Equity
45
N/A
42
-6%
47
+13%
42
-10%
45
+6%
51
+13%
53
+5%
55
+4%
58
+4%
53
-8%
49
-8%
47
-4%
47
+1%
44
-6%
44
-1%
45
+3%
44
-2%
41
-7%
46
+13%
47
+0%
49
+5%
47
-3%
48
+2%
Shares Outstanding
Common Shares Outstanding
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14